Drugs / IN026
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07587684 | May 2026 → Aug 2027 expected | gout | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07587684 ↗ |
| Known as | IN026 Injection | “IN026 Injection is a lipid nanoparticle (LNP)-formulated mRNA therapeutic administered as an intravenous (IV) infusion” NCT07587684 ↗ |
| Modality | Messenger RNA (mRNA) | “IN026 Injection is a lipid nanoparticle (LNP)-formulated mRNA therapeutic” NCT07587684 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT07587684 ↗ |